We are currently recruiting study participants for the following studies:

1.     A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma

The consent form outlining the study details can be found here.

2.       A phase 2 multi-centre randomized double-blind placebo-controlled parallel group study to examine the effects of 24 weeks tezepelumab 210 mg sc q4wks on methacholine airway hyperresponsiveness in participants with mild allergic asthma.

Click here to access the consent form which provides all the study details.